311 related articles for article (PubMed ID: 32542684)
1. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
2. Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study.
Wang M; Zhang L; Jia M; Wang J; Shen Z; Wang S; Zhang X; Xu J; Zheng Z; Lv X; Zong X; Li H; Zhou J; Meng T; Chen M; Zhao B; Gong J
BMC Nephrol; 2022 May; 23(1):191. PubMed ID: 35590283
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.
Wu B; Li D; Xu T; Luo M; He Z; Li Y
Sci Rep; 2021 Feb; 11(1):3690. PubMed ID: 33574396
[TBL] [Abstract][Full Text] [Related]
4. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Chen G; Qin Y; Fan QQ; Zhao B; Mei D; Li XM
Cancer Med; 2020 Sep; 9(18):6576-6585. PubMed ID: 32720449
[TBL] [Abstract][Full Text] [Related]
5. A pharmacovigilance study of association between proton-pump inhibitors and rhabdomyolysis event based on FAERS database.
Sun Y; Zhang A; Zuo M; Chen J; Zhu L
J Gastroenterol Hepatol; 2024 Feb; 39(2):289-296. PubMed ID: 37961012
[TBL] [Abstract][Full Text] [Related]
6. Associations of proton pump inhibitors and hospitalization due to hyponatremia: A population-based case-control study.
Falhammar H; Lindh JD; Calissendorff J; Skov J; Nathanson D; Mannheimer B
Eur J Intern Med; 2019 Jan; 59():65-69. PubMed ID: 30154038
[TBL] [Abstract][Full Text] [Related]
7. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.
Leonard CE; Bilker WB; Brensinger CM; Flockhart DA; Freeman CP; Kasner SE; Kimmel SE; Hennessy S
Stroke; 2015 Mar; 46(3):722-31. PubMed ID: 25657176
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor as an independent factor of progression of abdominal aortic calcification in patients on maintenance hemodialysis.
Okamoto T; Hatakeyama S; Hosogoe S; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Suzuki T; Ohyama C
PLoS One; 2018; 13(7):e0199160. PubMed ID: 29969455
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
10. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
11. Time-to-onset Analysis of Rhabdomyolysis due to Different Proton Pump Inhibitors Using a Pharmacovigilance Database.
Ohyama K; Iida M; Akiyama S; Yamazaki H; Hori Y
In Vivo; 2024; 38(3):1285-1291. PubMed ID: 38688634
[TBL] [Abstract][Full Text] [Related]
12. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
13. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
14. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
Clark DW; Strandell J
Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
[TBL] [Abstract][Full Text] [Related]
15. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
16. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
17. Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Lu B; Zhang L; Wang J; Wang B; Zou X; Fei G; Chen D; Wang X; Wu B; Zou D
J Gastroenterol Hepatol; 2018 Oct; 33(10):1722-1727. PubMed ID: 29575167
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
19. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
20. Use of proton pump inhibitors and macrolide antibiotics and risk of acute kidney injury: a self-controlled case series study.
Ikuta K; Nakagawa S; Yamawaki C; Itohara K; Hira D; Imai S; Yonezawa A; Nakagawa T; Sakuragi M; Sato N; Uchino E; Yanagita M; Terada T
BMC Nephrol; 2022 Nov; 23(1):383. PubMed ID: 36451129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]